hepatitis b vaccines

Summary

Summary: Vaccines or candidate vaccines containing inactivated hepatitis B or some of its component antigens and designed to prevent hepatitis B. Some vaccines may be recombinantly produced.

Top Publications

  1. ncbi Failure to respond to hepatitis B vaccine in children with celiac disease
    Seung Dae Park
    Division of Pediatric Gastroenterology and Nutrition, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
    J Pediatr Gastroenterol Nutr 44:431-5. 2007
  2. ncbi Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination
    Xiaofeng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Vaccine 27:6550-7. 2009
  3. ncbi Hepatitis B virus infection: epidemiology and vaccination
    Colin W Shepard
    Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Epidemiol Rev 28:112-25. 2006
  4. ncbi A mathematical model to estimate global hepatitis B disease burden and vaccination impact
    Susan T Goldstein
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Int J Epidemiol 34:1329-39. 2005
  5. ncbi Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
    D Lavanchy
    World Health Organization, Department of Communicable Diseases Surveillance and Response, Geneva, Switzerland
    J Clin Virol 34:S1-3. 2005
  6. ncbi The worldwide impact of vaccination on the control and protection of viral hepatitis B
    Luisa Romano'
    Dipartimento di Sanità Pubblica Microbiologia Virologia, Universita degli Studi di Milano, Milano, Italy
    Dig Liver Dis 43:S2-7. 2011
  7. ncbi Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program
    Brian J McMahon
    Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA
    Hepatology 54:801-7. 2011
  8. ncbi Hepatitis B vaccines: protective efficacy and therapeutic potential
    M L Michel
    Laboratoire de pathogenèse des virus de l hépatite B, Institut Pasteur, Batiment Lwoff, 28, rue du Docteur Roux, 75724 Paris Cedex 15, France
    Pathol Biol (Paris) 58:288-95. 2010
  9. ncbi The global impact of vaccination against hepatitis B: a historical overview
    Alessandro R Zanetti
    Department of Public Health Microbiology Virology, Faculty of Medicine, University of Milan, Via C Pascal 36, 20133 Milan, Italy
    Vaccine 26:6266-73. 2008
  10. ncbi Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies
    Yen Hsuan Ni
    Department of Pediatrics, Hospital and College of Medicine, National Taiwan University, Genomics Research Center, Taipei, Taiwan
    Gastroenterology 132:1287-93. 2007

Detail Information

Publications317 found, 100 shown here

  1. ncbi Failure to respond to hepatitis B vaccine in children with celiac disease
    Seung Dae Park
    Division of Pediatric Gastroenterology and Nutrition, North Shore Long Island Jewish Health System, New Hyde Park, NY, USA
    J Pediatr Gastroenterol Nutr 44:431-5. 2007
    ..To determine whether children with celiac disease (CD) fail to show a response to hepatitis B virus (HBV) vaccine more frequently than children without CD...
  2. ncbi Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination
    Xiaofeng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    Vaccine 27:6550-7. 2009
    ....
  3. ncbi Hepatitis B virus infection: epidemiology and vaccination
    Colin W Shepard
    Epidemiology Branch, Division of Viral Hepatitis, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Epidemiol Rev 28:112-25. 2006
    ....
  4. ncbi A mathematical model to estimate global hepatitis B disease burden and vaccination impact
    Susan T Goldstein
    Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
    Int J Epidemiol 34:1329-39. 2005
    ..Limited data are available regarding global hepatitis B virus (HBV)-related morbidity and mortality and potential reduction in disease burden from hepatitis B vaccination...
  5. ncbi Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention
    D Lavanchy
    World Health Organization, Department of Communicable Diseases Surveillance and Response, Geneva, Switzerland
    J Clin Virol 34:S1-3. 2005
    ....
  6. ncbi The worldwide impact of vaccination on the control and protection of viral hepatitis B
    Luisa Romano'
    Dipartimento di Sanità Pubblica Microbiologia Virologia, Universita degli Studi di Milano, Milano, Italy
    Dig Liver Dis 43:S2-7. 2011
    ..Despite this success, work remains to be done to fully achieve the WHO goal of control of hepatitis B and HBV-related diseases on a global scale...
  7. ncbi Elimination of hepatocellular carcinoma and acute hepatitis B in children 25 years after a hepatitis B newborn and catch-up immunization program
    Brian J McMahon
    Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, AK 99508, USA
    Hepatology 54:801-7. 2011
    ..The number of identified hepatitis B surface antigen-positive children <20 years in the Alaska Native population declined from 657 in 1987 to two in 2008...
  8. ncbi Hepatitis B vaccines: protective efficacy and therapeutic potential
    M L Michel
    Laboratoire de pathogenèse des virus de l hépatite B, Institut Pasteur, Batiment Lwoff, 28, rue du Docteur Roux, 75724 Paris Cedex 15, France
    Pathol Biol (Paris) 58:288-95. 2010
    ..Vaccination is the measure that is most effective in reducing the global incidence of hepatitis B and hepatitis B vaccines have now been available for over 20 years...
  9. ncbi The global impact of vaccination against hepatitis B: a historical overview
    Alessandro R Zanetti
    Department of Public Health Microbiology Virology, Faculty of Medicine, University of Milan, Via C Pascal 36, 20133 Milan, Italy
    Vaccine 26:6266-73. 2008
    ..A future challenge is to overcome the social and economic hurdles which still hamper the introduction of hepatitis B vaccination on a global scale...
  10. ncbi Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies
    Yen Hsuan Ni
    Department of Pediatrics, Hospital and College of Medicine, National Taiwan University, Genomics Research Center, Taipei, Taiwan
    Gastroenterology 132:1287-93. 2007
    ....
  11. ncbi Recommendations for identification and public health management of persons with chronic hepatitis B virus infection
    Cindy M Weinbaum
    Division of Viral Hepatitis, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, 1600 Clifton Road, MS G 37, Atlanta GA 30333, USA
    MMWR Recomm Rep 57:1-20. 2008
    ..This report is intended to serve as a resource for public health officials, organizations, and health-care professionals involved in the development, delivery, and evaluation of prevention and clinical services...
  12. ncbi Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study
    Mei Hwei Chang
    Department of Pediatrics, National Taiwan University Hospital, Chung Shan S Road, Taipei, Taiwan
    J Natl Cancer Inst 101:1348-55. 2009
    ....
  13. ncbi Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China
    Xiaofeng Liang
    Chinese Center for Disease Control and Prevention, Beijing, China
    J Infect Dis 200:39-47. 2009
    ..Endemic hepatitis B virus (HBV) infection is a serious health problem in China. Hepatitis B vaccination of infants was introduced in 1992 and was progressively expanded during the subsequent 15 years...
  14. ncbi Hepatitis B vaccines
    Daniel Shouval
    Hadassah Medical Organization, Hadassah University Hospital, 91120 Jerusalem, Israel
    J Hepatol 39:S70-6. 2003
    Yeast-derived hepatitis B vaccines, containing the small HBV envelope protein SHBAg, are immunogenic, safe and cost-effective in prevention of hepatitis B virus infection in neonates, children and adults...
  15. pmc Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis
    Chuanfang Lee
    Cochrane Hepato Biliary Group, Copenhagen Trial Unit, Copenhagen University Hospital, Denmark
    BMJ 332:328-36. 2006
    ..To evaluate the effects of hepatitis B vaccine and immunoglobulin in newborn infants of mothers positive for hepatitis B surface antigen...
  16. ncbi Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose
    Brian J McMahon
    Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA
    J Infect Dis 200:1390-6. 2009
    ..The duration of protection in children and adults (including health care workers) resulting from the hepatitis B vaccine primary series is unknown...
  17. ncbi A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults
    Eric E Mast
    Division of Viral Hepatitis, National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention proposed, Atlanta, GA 30333, USA
    MMWR Recomm Rep 55:1-33; quiz CE1-4. 2006
    ....
  18. ncbi Impacts of vaccination on hepatitis B viral infections in Korea over a 25-year period
    Neung Hwa Park
    Department of Internal Medicine and Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
    Intervirology 53:20-8. 2010
    ..Hepatitis B virus (HBV) vaccination has effectively reduced the acute and chronic infection rates in recent years. Since 1983, HBV vaccination has been recommended for all neonates in Korea...
  19. ncbi Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study
    W M Xu
    Shanghai Infectious Disease Hospital, Shanghai, China
    J Viral Hepat 16:94-103. 2009
    ..Results of this study suggest that lamivudine reduced HBV transmission from highly viraemic mothers to their infants who received passive/active immunization...
  20. ncbi The prevalence of hepatitis B virus infection in the United States in the era of vaccination
    Annemarie Wasley
    National Center for HIV AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    J Infect Dis 202:192-201. 2010
    ..Our objective was to assess trends in the prevalence of hepatitis B virus (HBV) infection in the United States after widespread hepatitis B vaccination...
  21. ncbi Current status of liver diseases in Korea: hepatitis B
    Hee Bok Chae
    Department of Internal Medicine, Chungbuk National Unviersity College of Medicine, Cheongju, Korea
    Korean J Hepatol 15:S13-24. 2009
    ..2% after the nationwide vaccination program. Although hepatitis B vaccines are highly effective, the failure rate of perinatal prophylaxis in babies born to HBsAg positive mother was ..
  22. ncbi The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity
    Nancy Bermal
    Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntinlupa City, The Philippines
    Pediatr Infect Dis J 28:S89-96. 2009
    ....
  23. ncbi Epidemiology and prevention of hepatitis B virus infection in China
    F M Lu
    Department of Microbiology, Peking University Health Science Center, Beijing, China
    J Viral Hepat 17:4-9. 2010
    ..More efforts are needed to improve and develop strategies for the control of HBV infection in China, particularly after implementing the policy of universal HBV immunization for all newborns...
  24. pmc DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model
    Anna D Kosinska
    Institute of Virology, University Hospital of Essen, Essen, Germany
    J Virol 86:9297-310. 2012
    ..Therefore, this new vaccination strategy may be a candidate for a therapeutic vaccine against chronic HBV infection...
  25. pmc Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count
    Michael L Landrum
    Infectious Disease Clinical Research Program, Uniformed Services University, Bethesda, MD, USA
    Vaccine 27:4731-8. 2009
    ..These data provide additional evidence of HAART benefits, even in those with higher CD4 counts, but also highlight the need for improving HBV vaccine immunogenicity...
  26. ncbi Increased regulatory T cell counts in HIV-infected nonresponders to hepatitis B virus vaccine
    Maria Del Mar Del Pozo Balado
    Immunovirology Laboratory, Infectious Diseases Service, Clinical Biochemistry Service, Institute of Biomedicine of Seville IBIS, Virgen del Rocio University Hospital, Seville, Spain
    J Infect Dis 202:362-9. 2010
    ..These findings suggest an active role played by T(reg) cells on the immunization antigen-specific T and/or B cell responses with the final consequence of a B cell anti-HBs lower production...
  27. ncbi Physicochemical and immunological characterization of hepatitis B virus envelope particles exclusively consisting of the entire L (pre-S1 + pre-S2 + S) protein
    T Yamada
    Department of Structural Molecular Biology, Institute of Scientific and Industrial Research SANKEN, Osaka University, 8 1 Mihogaoka, 567 0047, Ibaraki, Japan
    Vaccine 19:3154-63. 2001
    ..These results show the high ability of L particles to induce all antibodies against HBV env proteins, hence promising the future application of L particles for the next generation HB vaccine...
  28. ncbi HLA and cytokine gene polymorphisms are independently associated with responses to hepatitis B vaccination
    Chengbin Wang
    Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Hepatology 39:978-88. 2004
    ..In conclusion, DRB1*07 (or a closely linked allele) and immunoregulatory cytokine gene polymorphisms correlate with variable immune response to recombinant HBV vaccines...
  29. pmc Prevalence of HBV and HBV vaccination coverage in health care workers of tertiary hospitals of Peshawar, Pakistan
    Sobia Attaullah
    Institute of Basic Medical Sciences, Khyber Medical University Peshawar, Pakistan
    Virol J 8:275. 2011
    ..Hepatitis B vaccination coverage level and main barriers to vaccination were also taken in account...
  30. ncbi Vaccination against hepatitis B among prisoners in Iran: accelerated vs. classic vaccination
    Ali Asghar Zolghadr Asli
    Islamic Azad University, Istahban Branch, Istahban, Iran
    Health Policy 100:297-304. 2011
    ..In this randomized clinical trial we investigated the efficacy of an accelerated vaccination protocol vs. classic schedule among prisoners in Iran...
  31. ncbi N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus
    Corinna M Bremer
    Institute of Medical Virology, Justus Liebig University, D 35392 Giessen, Germany
    J Hepatol 55:29-37. 2011
    ..Its B-cell epitopes leading to neutralization of infectivity are not yet characterized...
  32. ncbi Hepatitis B in healthcare workers: prevalence, vaccination and relation to occupational factors
    Luiz A S Ciorlia
    Epidemiology and Public Health Department, Medical School of São José do Rio Preto, Rua Santo Agostinho 281, Sao Jose do Rio Preto, SP, Brazil
    Braz J Infect Dis 9:384-9. 2005
    ..There was a higher seroconversion in HCW who received the full set of HBV vaccines. In HCW with positive serology, the factors that presented greatest risks were time in service, work-related injuries and maximum risk sector...
  33. ncbi A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents
    Eric E Mast
    Division of Viral Hepatitis, National Center for Infectious Diseases, USA
    MMWR Recomm Rep 54:1-31. 2005
    ..The second part of the ACIP statement, which will include updated recommendations and strategies to increase hepatitis B vaccination of adults, will be published separately...
  34. ncbi Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigen-positive mothers in Italy
    A Mele
    Clinical Epidemiology Unit, Istituto Superiore di Sanita, Rome, Italy
    J Infect Dis 184:905-8. 2001
    ..There is no evidence that the emergence of HBV escape mutants secondary to the immune pressure against wild-type HBV is of concern...
  35. pmc Evidence of protection against clinical and chronic hepatitis B infection 20 years after infant vaccination in a high endemicity region
    Y Poovorawan
    Department of Pediatrics, Faculty of Medicine, Center of Excellence in Clinical Virology, Chulalongkorn University, Bangkok, Thailand
    J Viral Hepat 18:369-75. 2011
    ..Primary infant vaccination with a recombinant hepatitis B vaccine confers long-term protection against clinical disease and new chronic hepatitis B infection despite confirmed hepatitis B exposure...
  36. ncbi Hepatitis B and the need for a booster dose
    Elke Leuridan
    Centre for the Evaluation of Vaccination, Vaccine and Infectious Disease Institute, Faculty of Medicine, University of Antwerp, Edegem, Belgium
    Clin Infect Dis 53:68-75. 2011
    ..However, a booster dose should be planned for immunocompromised patients, based on serological monitoring...
  37. ncbi Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand
    Yong Poovorawan
    Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
    Vaccine 28:730-6. 2010
    ..Higher persisting seroprotection rates in subjects boosted at Year 5 did not translate into apparent differences in immune memory in a high endemic country...
  38. ncbi Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease
    F Fabrizi
    Center for Liver and Kidney Diseases and Transplantation, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Aliment Pharmacol Ther 20:1053-62. 2004
    ..Age-associated changes in immune status may contribute to decreased vaccine efficacy in older individuals although contradictory results have been reported in individuals with normal kidney function...
  39. ncbi Molecular analysis of HLA class II associations with hepatitis B virus clearance and vaccine nonresponsiveness
    Andrew Godkin
    Cellular Immunology and Vaccine Development Group, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford, United Kingdom
    Hepatology 41:1383-90. 2005
    ....
  40. ncbi Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients
    Martijn A Verkade
    Erasmus Medical Center, Department of Internal Medicine, Division of Nephrology, Dijkzigt Rottterdam, The Netherlands
    Kidney Int 66:614-21. 2004
    ..Although GM-CSF acts on both monocytes and dendritic cells, the mechanisms underlying its adjuvant quality are largely unknown...
  41. ncbi Vaccination against hepatitis B: the Chinese experience
    Yi Hua Zhou
    Department of Laboratory Medicine, Nanjing Drum Tower Hospital, Nanjing University Medical School, Jiangsu, China
    Chin Med J (Engl) 122:98-102. 2009
    ..To review the implementation of mass vaccination of hepatitis B vaccine and its critical role in prevention of hepatitis B virus infection in China...
  42. ncbi Seroprevalence of hepatitis B surface antigen among pregnant women in Jiangsu, China, 17 years after introduction of hepatitis B vaccine
    Shu Zhang
    Department of Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, China
    Int J Gynaecol Obstet 109:194-7. 2010
    ..To estimate the prevalence of hepatitis B surface antigen (HBsAg) among pregnant women in Jiangsu Province, eastern China, 17years after vaccination against hepatitis B virus (HBV) was introduced...
  43. pmc Survey of HBsAg-positive pregnant women and their infants regarding measures to prevent maternal-infantile transmission
    Yan Guo
    The Department of Maternal and Child Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 430030, China
    BMC Infect Dis 10:26. 2010
    ..31th, 2006 in Wuhan City, China. We investigated the measures taken to prevent maternal-infantile transmission of hepatitis B virus and the infection status of children...
  44. pmc Immunization with the gene expressing woodchuck hepatitis virus nucleocapsid protein fused to cytotoxic-T-lymphocyte-associated antigen 4 leads to enhanced specific immune responses in mice and woodchucks
    Mengji Lu
    Institut fur Virologie, Universitatsklinikum Essen, Hufelandstrasse 55, Essen D 45122, Germany
    J Virol 79:6368-76. 2005
    ..In conclusion, the use of fusion genes represents a generally applicable strategy to improve DNA vaccination...
  45. ncbi Clinical practice: prevention of hepatitis B with the hepatitis B vaccine
    Gregory A Poland
    Mayo Vaccine Research Group, Program in Translational Immunovirology and Biodefense, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    N Engl J Med 351:2832-8. 2004
  46. ncbi Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination
    Chun Yi Lu
    Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan
    Hepatology 40:1415-20. 2004
    ..In conclusion, our findings suggest that one or more booster immunizations are needed in seronegative subjects by at least 15 years following neonatal immunization with plasma-derived HB vaccine...
  47. ncbi Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunization
    Selidji T Agnandji
    Albert Schweitzer Hospital, Medical Research Unit Lambaréné, Lambarene, Gabon
    J Infect Dis 202:1076-87. 2010
    ..The RTS,S/AS01(E) malaria candidate vaccine is being developed for immunization of African infants through the Expanded Program of Immunization (EPI)...
  48. ncbi Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination
    Y H Ni
    National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 100, Taiwan
    Ann Intern Med 135:796-800. 2001
    ..By decreasing the carrier pool, continuation of the national HBV immunization program should prevent HBV infection in the children of Taiwan, and, subsequently, adults as well...
  49. pmc Host genetic factors and vaccine-induced immunity to hepatitis B virus infection
    Branwen J Hennig
    London School of Hygiene and Tropical Medicine, London, United Kingdom
    PLoS ONE 3:e1898. 2008
    ..We investigated the role of host genetic factors in long-term immunity against HBV infection based on peak anti-HBs level and seroconversion to anti-HBc...
  50. ncbi Immunogenicity of a novel, bivalent, plant-based oral vaccine against hepatitis B and human immunodeficiency viruses
    Sergei N Shchelkunov
    State Research Center of Virology and Biotechnology Vector, Koltsovo, Novosibirsk Region, 630559, Russia
    Biotechnol Lett 28:959-67. 2006
    ..Intraperitoneal injection of a DNA vaccine directing synthesis of the same TBI-HBsAg antigen boosted the antibody response to HIV in the blood serum; however, it had no effect on the high level of antibodies produced to HBV...
  51. ncbi Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan
    Yu Cheng Lin
    Department of Pediatrics, National Taiwan University Hospital and National Taiwan University, College of Medicine, Taipei, Taiwan
    J Infect Dis 187:134-8. 2003
    ..The results suggest that routine booster vaccination may not be required to provide protection against chronic HBV infection before age 15 years...
  52. ncbi Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine
    Pamela Rendi-Wagner
    Department of Specific Prophylaxis and Tropical Medicine, Medical University Vienna, Kinderspitalgasse 15, A 1090 Vienna, Austria
    Vaccine 24:2781-9. 2006
    Conventional hepatitis B vaccines do not elicit adequate antibody production in 5-10% vaccinees...
  53. ncbi Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects
    Scott E Kellerman
    Surveillance Branch, Division of HIV AIDS Prevention, Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia 30306, USA
    J Infect Dis 188:571-7. 2003
    ..HBV remains an important cause of comorbidity in HIV-infected persons, but ART and vaccination are associated with decreased disease...
  54. ncbi Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines
    Jacek Wysocki
    University School of Medical Sciences and Regional Medical Center for Mother and Child, Poznan, Poland
    Pediatr Infect Dis J 28:S77-88. 2009
    ....
  55. ncbi Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up
    Brian J McMahon
    Arctic Investigations Program, National Center for Infectious Diseases, Centers for Disease Control and Prevention, and the Alaska Native Medical Center, Anchorage, Alaska 99508, USA
    Ann Intern Med 142:333-41. 2005
    ..The duration of protection afforded by hepatitis B vaccination is unknown...
  56. ncbi Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched
    Yin Chu Chien
    Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Taipei, Taiwan
    Epidemiol Rev 28:126-35. 2006
    ..In conclusion, since 1984, the national hepatitis B vaccination program has been successful in preventing acute and chronic liver diseases in Taiwan...
  57. ncbi Hepatitis B vaccination in children: the Taiwan experience
    Y H Ni
    Department of Pediatrics, National Taiwan University Children s Hospital, Taipei, Taiwan
    Pathol Biol (Paris) 58:296-300. 2010
    ..The emergence of escape mutant did not impose increased risk of chronic infection at present. Nevertheless, development of new vaccines may overcome the vaccine failure...
  58. ncbi Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines
    Bertrand Chevallier
    Service de Pediatrie, Hopital Louis Mourier, Colombes, France
    Pediatr Infect Dis J 28:S109-18. 2009
    ....
  59. ncbi Adult immunizations: update on recommendations
    Huan Pham
    Division of Infectious Diseases, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
    Am J Med 124:698-701. 2011
    ..Hepatitis B vaccination should be encouraged in non-immune adults. Recommendations also address vaccinations for tetanus/diphtheria, hepatitis A, pneumococcus, measles/mumps/rubella, and meningococcus...
  60. pmc Cancer in the Gambia: 1988-97
    E Bah
    International Agency for Research on Cancer, c o The Gambia Hepatitis Intervention Study, MRC Laboratories, Fajara PO Box 273, Banjul, The Gambia
    Br J Cancer 84:1207-14. 2001
    ..It is hoped that immunization of children under 1 year against hepatitis B will drastically reduce the incidence of liver cancer in The Gambia...
  61. ncbi Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children
    S S Liao
    Institute of Basic Medical Sciences, Peking Union Medical College, Beijing, People s Republic of China
    Vaccine 17:2661-6. 1999
    ..02). 28 chronic HBsAg carriers were identified in the control cohort over the 15 years, whereas only 1 case was noted in the vaccinated group (8.2% vs. 0.3%, P < 0.00001), corresponding to an efficacy of 96%...
  62. pmc Hepatitis B vaccination among a national sample of gay and bisexual men
    Paul L Reiter
    UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Sex Transm Dis 38:235-8. 2011
    ..Hepatitis B virus vaccination was higher among men who were 18 to 29 years old (compared to those 50-59 years old), gay, or had received flu vaccine within the last year...
  63. ncbi Hydrogel-delivered GM-CSF overcomes nonresponsiveness to hepatitis B vaccine through the recruitment and activation of dendritic cells
    Ho Yuan Chou
    Graduate Institute of Microbiology, National Taiwan University, Taipei, Taiwan
    J Immunol 185:5468-75. 2010
    ..These results demonstrate that hydrogel-formulated GM-CSF might represent a simple and effective method to generate next-generation hepatitis B virus vaccines for inducing anti-hepatitis B surface Abs in nonresponders...
  64. ncbi Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV/Hib and poliovirus vaccines
    Nancy Bermal
    Research Institute for Tropical Medicine, Filinvest Corporate City, Alabang, Muntinlupa City, Philippines
    Pediatr Infect Dis J 30:69-72. 2011
    ..Robust immune responses for all 10 vaccine pneumococcal serotypes and protein D following PHiD-CV booster vaccination were indicative of effective priming...
  65. ncbi Frequency of hepatitis B immunity and occupational exposures to body fluids among Brazilian medical students at a public university
    Luiz Carlos Marques de Oliveira
    Departamento de Clinica Medica, Faculdade de Medicina, Universidade Federal de Uberlandia, Uberlandia, MG, Brasil
    Rev Inst Med Trop Sao Paulo 52:247-52. 2010
    ....
  66. pmc Low-dose oral immunization with lyophilized tissue of herbicide-resistant lettuce expressing hepatitis B surface antigen for prototype plant-derived vaccine tablet formulation
    Tomasz Pniewski
    Institute of Plant Genetics, Polish Academy of Sciences, Strzeszynska 34, 60 479, Poznan, Poland
    J Appl Genet 52:125-36. 2011
    ..The results of the study provide indications on immunization methodology using a durable, efficacious, and convenient plant-derived prototype oral vaccine against hepatitis B...
  67. ncbi Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines
    T Coates
    The Queen Elizabeth Hospital, Woodville, South Australia
    Clin Ther 23:392-403. 2001
    ..OBJECTIVE: This parallel analysis of 2 recombinant hepatitis B vaccines (Engerix B and Recombivax/HB-Vax II) was conducted to review the seroprotective efficacy of each vaccine in ..
  68. ncbi The first five years of universal hepatitis B vaccination in South Africa: evidence for elimination of HBsAg carriage in under 5-year-olds
    K V Tsebe
    Department of Virology, Medical University of Southern Africa, Pretoria, 0204 Gauteng Province, South Africa
    Vaccine 19:3919-26. 2001
    ..It can be concluded that the HBV vaccine is highly effective within the framework of the South African EPI and already shows a positive impact in the elimination of HBsAg carrier rate in children<5 years...
  69. ncbi High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG
    Sajad Shahmoradi
    Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
    J Hepatol 57:515-21. 2012
    ..We aimed at determining the prevalence of occult HBV infection in a high risk group of children who developed HBV infection despite immunoprophylaxis...
  70. ncbi No increase in prevalence of hepatitis B surface antigen mutant in a population of children and adolescents who were fully covered by universal infant immunization
    Hong Yuan Hsu
    Department of Pediatrics, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan
    J Infect Dis 201:1192-200. 2010
    ..Mutants of the a determinant of hepatitis B surface antigen (HBsAg) can escape neutralization by vaccine-induced antibodies and prevail in an immunized population...
  71. ncbi Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults
    D V Potsch
    HUCFF FM Universidade Federal do Rio de Janeiro, Brazil
    Vaccine 30:5973-7. 2012
    ..Antibody responses to standard regimens of hepatitis B (HBV) vaccination are lower in HIV-infected subjects and the best hepatitis B vaccine schedule in this population is not known...
  72. ncbi Efficacy of yeast-derived recombinant hepatitis B vaccine after being used for 12 years in highly endemic areas in China
    Liping Shen
    Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
    Vaccine 30:6623-7. 2012
    ..To evaluate the long-term efficacy and duration of yeast-derived recombinant hepatitis B vaccine in hepatitis B virus (HBV)-endemic areas...
  73. ncbi Determinants of Long-term protection after hepatitis B vaccination in infancy: a meta-analysis
    Katharina Schönberger
    Institute of Social Pediatrics and Adolescent Medicine, Division of Epidemiology, Biostatistics and Epidemiology, Ludwig Maximilians University of Munich, Germany
    Pediatr Infect Dis J 32:307-13. 2013
    ..Factors potentially influencing waning immunity were assessed...
  74. ncbi Hepatitis B immunisation programmes in European Union, Norway and Iceland: where we were in 2009?
    Jolita Mereckiene
    Health Protection Surveillance Centre, Dublin, Ireland Vaccine European New Integrated Collaboration Effort VENICE Project, Italy
    Vaccine 28:4470-7. 2010
    ..Among countries without universal hepatitis B vaccination programmes, the major factor for non-introduction is low disease endemicity...
  75. ncbi Risk of hepatitis B transmission in breast-fed infants of chronic hepatitis B carriers
    James B Hill
    Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, 75235 9032, USA
    Obstet Gynecol 99:1049-52. 2002
    ..To measure the rate of hepatitis B (HBV) transmission from chronic HBV carriers to breast-fed infants after immunoprophylaxis...
  76. ncbi Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants
    Guillermo M Ruiz-Palacios
    Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Tlalpan, Mexico
    Hum Vaccin 7:1137-45. 2011
    ..PHiD-CV was well tolerated, with no serious adverse events considered as causally related to vaccination. Most solicited symptoms were mild and there was no increase in incidence of solicited symptoms with successive vaccine doses...
  77. pmc Accelerated hepatitis B vaccination schedule among drug users: a randomized controlled trial
    Lu Yu Hwang
    Center for Infectious Diseases, Division of Epidemiology and Disease Control, School of Public Health, University of Texas Health Science Center at Houston, Houston, Texas 77030, USA
    J Infect Dis 202:1500-9. 2010
    ..Hepatitis B vaccine provides a model for improving uptake and completion of multidose vaccinations in the drug-using community...
  78. ncbi The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran
    Mehdi Saberifiroozi
    Gastroenterohepatology Research Center, Nemazee Hospital, Shiraz, Iran
    Arch Iran Med 9:204-7. 2006
    ..This study was conducted to evaluate the long-term efficacy of HBV vaccine in health care workers and the need for their reassessment for revaccination...
  79. ncbi Evaluation of the compliance with the protocol for preventing perinatal hepatitis B infection in Italy
    Enea Spada
    National Centre of Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita, Rome, Italy
    J Infect 62:165-71. 2011
    ..To evaluate the compliance with the protocol for preventing perinatal hepatitis B infection in Italy, including HBsAg screening of pregnant women and immunization of newborns to infected mothers...
  80. ncbi Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers
    Yong Poovorawan
    Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Thailand
    J Infect Dis 200:33-8. 2009
    ..Transmission of hepatitis B virus (HBV) from carrier mothers to their babies appears to be one of the most important factors influencing the prevalence of chronic HBV infection in areas of high hepatitis B endemicity...
  81. ncbi Mother-to-infant transmission of hepatitis B virus: a Chinese experience
    Zhong jun Shao
    Department of Epidemiology, School of Public Health, The Fourth Military Medical University, Xi an, China
    J Med Virol 83:791-5. 2011
    ..These results indicate that infants infected via intrauterine transmission cannot be effectively protected by HBIG and HB vaccine...
  82. ncbi Real time monitoring of antigenicity development of HBsAg virus-like particles (VLPs) during heat- and redox-treatment
    Qinjian Zhao
    Merck Research Laboratories, West Point, PA 19486, USA
    Biochem Biophys Res Commun 408:447-53. 2011
    ....
  83. pmc Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals
    Michael L Landrum
    San Antonio Military Medical Center, Fort Sam Houston, TX 78234, USA
    AIDS 24:545-55. 2010
    ..To assess the association of hepatitis B virus (HBV) vaccination with risk of HBV infection among HIV-infected patients and HBV infection risk factors among vaccinees...
  84. ncbi Recombinant hepatitis B core antigen carrying preS1 epitopes induce immune response against chronic HBV infection
    Xinchun Chen
    Shenzhen Institute of Hepatology, 2019 Buxin Road, Shenzhen 518020, PR China
    Vaccine 22:439-46. 2004
    ..HBVCS1 vaccination reduced of the titer of HBsAg and HBV DNA in sera of HBV-Tg mice. These results indicate that HBVCS1 may have potential as a therapeutic vaccine for treatment of HBV chronic infection...
  85. ncbi In-depth process understanding of RECOMBIVAX HB® maturation and potential epitope improvements with redox treatment: multifaceted biochemical and immunochemical characterization
    Qinjian Zhao
    Merck Research Laboratories, Merck and Co, Inc, West Point, PA 19486, USA
    Vaccine 29:7936-41. 2011
    ..Taken together, these quantitative analytical tools enable more rapid, in-depth, and comprehensive process monitoring, process optimization, and assessment of product consistency and stability...
  86. ncbi Evaluation of the compliance with recommended procedures in newborns exposed to HBsAg-positive mothers: a multicenter collaborative study
    Ulrich Heininger
    Division of Pediatric Infectious Diseases, University Children s Hospital Basel, Switzerland
    Pediatr Infect Dis J 29:248-50. 2010
    ..The purpose of this study was to determine the compliance with official recommendations for prevention of perinatal HBV transmission in hepatitis B surface antigen (HBsAg) exposed infants...
  87. ncbi A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients
    N C T Kong
    1Nephroloyg Dialysis Unit, Department of Medicine, National University Hospital of Malaysia, Kuala Lumpur, Malaysia
    Kidney Int 73:856-62. 2008
    ..patients are at an increased risk of hepatitis B infection and have an impaired immune response to hepatitis B vaccines. We evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in this ..
  88. ncbi Increased risk of developing chronic HBV infection in infants born to chronically HBV infected mothers as a result of delayed second dose of hepatitis B vaccination
    Piyanit Tharmaphornpilas
    Immunization Program, Bureau of General Communicable Diseases, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand
    Vaccine 27:6110-5. 2009
    ..Nevertheless, due to the small sample size, these findings should be verified by larger studies...
  89. ncbi Impact of hepatitis B vaccination in children born to HBsAg-positive mothers: a 20-year retrospective study
    L Bracciale
    Department of Molecular Biology, Infectious Diseases Clinic, Siena University, Siena, Italy
    Infection 37:340-3. 2009
    ..Preventive measures remain the best approach to control the spread of hepatitis B virus (HBV) infection...
  90. ncbi Quantitative analysis of HBV DNA level and HBeAg titer in hepatitis B surface antigen positive mothers and their babies: HBeAg passage through the placenta and the rate of decay in babies
    Zhanhui Wang
    Department of Infectious Disease, Nanfang Hospital, The First Medical College of PLA, Guangzhou 510 515, China
    J Med Virol 71:360-6. 2003
    ..HBV DNA levels in hepatitis B carrier mothers are associated with the failure of HBIG and vaccine immunization, and the additional influence of transmitted HBeAg cannot be excluded...
  91. ncbi European survey of hepatitis B vaccination policies for healthcare workers
    Antoon De Schryver
    Department of Epidemiology and Social Medicine, University of Antwerp, Antwerp, Belgium
    Eur J Public Health 21:338-43. 2011
    ..Immunization should happen early after the start of their career to avoid infection and development of carrier status...
  92. ncbi The nonresponse to hepatitis B vaccination is associated with impaired lymphocyte activation
    Loredana Goncalves
    Institute of Clinical Immunology, University of Los Andes, Merida, Venezuela
    Virology 326:20-8. 2004
    ..In conclusion, our results suggest that an altered Th response may be a consequence of inappropriate early activation events...
  93. pmc The Young Men's Survey phase II: hepatitis B immunization and infection among young men who have sex with men
    Cindy M Weinbaum
    Office of Communications, NCHHSTP, Mailstop E 06, Centers for Disease Control and Prevention, 16000 Clifton Road, Atlanta GA 30333, USA
    Am J Public Health 98:839-45. 2008
    ..We measured the prevalence of hepatitis B virus (HBV) immunization and HBV infection among men aged 23 to 29 years who have sex with men...
  94. ncbi Vaccination against hepatitis B in health care workers
    P Bonanni
    Department of Public Health and Epidemiology, University of Florence, Viale G B Morgagni 48, 50134, Florence, Italy
    Vaccine 19:2389-94. 2001
    ..In the mean time, coverage with standard vaccines should be improved also by supplying complete information on the risks of hepatitis B and on the safety and efficacy of active immunisation...
  95. ncbi Toll-like receptors and cytokines/cytokine receptors polymorphisms associate with non-response to hepatitis B vaccine
    Jie Chen
    Department of Microbiology, Peking University Health Science Center, Beijing 100191, China
    Vaccine 29:706-11. 2011
    ..035). Thus, specific SNPs in genes of cytokines/cytokine receptors and TLR2 were associated with status of the hepatitis B vaccine-induced protective humoral immune response...
  96. ncbi A multi-center controlled study of rapid hepatitis B vaccination using a novel triple antigen recombinant vaccine
    M D Young
    Medeva Group Development, 1265 Drummers Lane, Suite 300, Wayne, PA 19087, USA
    Vaccine 19:3437-43. 2001
    b>Hepatitis B vaccines have been available for 20 years, however, the disease still remains a global problem...
  97. ncbi Influence of cytokine gene variations on immunization to childhood vaccines
    Berran Yucesoy
    Toxicology and Molecular Biology Branch, CDC NIOSH, Morgantown, WV 26505 2888, United States
    Vaccine 27:6991-7. 2009
    ..05). These data suggest that genetic variations in cytokine genes can influence vaccine-induced immune responses in infants, which in turn may influence vaccine efficacy...
  98. ncbi 20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer
    Simonetta Viviani
    IARC, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France
    Cancer Epidemiol Biomarkers Prev 17:3216-23. 2008
    ....
  99. ncbi Knowledge, attitudes, and behaviors of Chinese hepatitis B screening and vaccination
    Grace X Ma
    Department of Public Health, Director of Center for Asian Health, Temple University, Philadelphia, PA 19122 0843, USA
    Am J Health Behav 32:178-87. 2008
    ..To measure the knowledge, attitudes, and behaviors of Hepatitis B (HBV) screening and vaccination in the Chinese American population...
  100. pmc Factors relating to acceptance of hepatitis B virus vaccination by nursing students in a tertiary hospital, Pakistan
    Hafeez ur Rehman Mengal
    Bolan Medical College, Brewery Road, Balochistan, Quetta, Pakistan
    J Health Popul Nutr 26:46-53. 2008
    ..Health institutions should allocate adequate budgets to vaccinate their nursing students. Effective intervention programmes designed to increase knowledge about HBV infection and adhering to universally-accepted precautions are needed...
  101. ncbi Cancer control activities in the Republic of Korea
    Keun Young Yoo
    National Cancer Center, 111 Jungbalsan ro, Ilsandong gu, Goyang si, Gyeonggi do 410 769, Republic of Korea
    Jpn J Clin Oncol 38:327-33. 2008
    ....

Research Grants64

  1. Natural History and Prevention of Viral Hepatitis Among Alaska Natives
    BRIAN JAMES MCMAHON; Fiscal Year: 2013
    ..health issues by determining the further duration of vaccine protection afforded by both hepatitis A and hepatitis B vaccines in children and adults in well-established longitudinal cohorts...
  2. Modeling distinct neonatal purine metabolism to inform vaccine development
    Ofer Levy; Fiscal Year: 2013
    ..These studies will provide insight into neonatal immunity, establish novel platforms for studying immune ontogeny, assess Ado-refractory adjuvants, and inform neonatal vaccine development. ..
  3. NATURAL HISTORY PREVENTION OF VIRAL HEPATITIS IN ALASKA NATIVE PEOPLE
    BRIAN JAMES MCMAHON; Fiscal Year: 2012
    ..abstract_text> ..
  4. An Orally Delivered Hepatitis B Vaccine
    John Howard; Fiscal Year: 2009
    ..The technology should be applicable to other diseases as well. Preliminary research with hepatitis B vaccines candidates has demonstrated expression in maize and the ability to elicit an antibody response in mice...
  5. Stellenbosch University Clinical Trial Unit, Cape Town, South Africa
    MARK FREDRIC COTTON; Fiscal Year: 2013
    ..James Mclntyre, Perinatal HIV Research Unit ACTG, Witwatersrand University. Though this co-mentoring partnership, the AIDs CRS is expected to be able to enroll subjects within six months of funding. ADMINISTRATIVE COMPONENT: ..
  6. Towards a Vaccine for the Common Cold
    THOMAS JAMES SMITH; Fiscal Year: 2010
    ..If successful, the methods developed here will also yield a rapid way to identify potential, conserved, vaccine targets for other antigenically diverse viruses as well. ..
  7. Plant-Derived hepatitis B Vaccine from Biomanufacturing System to Clinical Trial
    Robert Britt; Fiscal Year: 2009
    ....
  8. Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans
    Anna Karolina Palucka; Fiscal Year: 2013
    ..abstract_text> ..
  9. Stability and functionality of the Immunoject single-dose, auto-reconstitution de
    Brian Quinn; Fiscal Year: 2010
    ..Key to Immunoject's potential is the innovative formulation of active ingredients as thermally stable and rapidly dissolving dry powders. ..
  10. A new, rapidly dissolving and thermally stable dry powder Hepatitis-B vaccine
    STEPHEN P CAPE; Fiscal Year: 2013
    ..The outcome of the Phase II work will be judged based on the potency of the Hep-B dry powder formulation and the functionality and performance of the BD device as compared with the potency of the needle and syringe administration. ..
  11. PREPARATION FOR AIDS/HIV VACCINE EVALUATIONS
    Susan Allen; Fiscal Year: 1993
    ..WHO will ensure the coordination of government and international groups involved in future AIDS/HIV vaccine trials in Rwanda...
  12. RANDOMIZED HEPATITIS B VACCINE DELIVERY TRIAL FOR IDUS
    Karen Seal; Fiscal Year: 2000
    ....
  13. INTERNATIONAL VACCINE PROGRAM
    Jean Pape; Fiscal Year: 1993
    ....
  14. HEPATITIS B VACCINE ACCEPTANCE AMONG STD PATIENTS
    Gregory Zimet; Fiscal Year: 1999
    ..The importance of vaccine characteristics in influencing vaccine choice will be evaluated with conjoint analysis, a technique often used in marketing research. ..
  15. VITAMIN A THERAPY IN PRETERM INFANTS: VACCINE RESPONSE
    Mark Ballow; Fiscal Year: 2002
    ..These factors could lead to decreased morbidity and mortality of pre-term infants during early postnatal life. ..
  16. BIODEGRADABLE MINERAL MICROSPHERE ADJUVANTS FOR VACCINES
    ELIE NUWAYSER; Fiscal Year: 1999
    ..needed to potentiate the immune response to hepatitis B surface antigen (HBsAg), the active constituent of hepatitis B vaccines, has been demonstrated utilizing BIOTEK s novel mineral microspheres...
  17. The Psychoneuroimmunology of Insomnia: Response to a Vaccine Challenge
    WILFRED PIGEON; Fiscal Year: 2009
    ....
  18. Innovative Single-Dose Hepatitis B Vaccine Formulation
    J Kitchell; Fiscal Year: 2002
    ..One important application in the future may be with an AIDS vaccine, where relaible single-dose protection for high risk populations may be especially important. ..
  19. Cutaneous Gene Therapy with Ultrasound: DNA Vaccination
    Samir Mitragotri; Fiscal Year: 2006
    ..3. Using an in vitro model, Epiderm, and in vivo mouse model, assess safety of skin exposure to low-frequency ultrasound. ..
  20. Psychological Stress and Immune Response to Vaccination
    ANNA MARSLAND; Fiscal Year: 2007
    ..Antibody responses will be measured at the time of the second and third does of vaccine and, during the follow-up period, 6 and 12 months following completion of the vaccination series. ..
  21. Multicolor Flow Users Network Study
    David Asmuth; Fiscal Year: 2004
    ..The panel developed in each of the AIMS above will be applied to these studies to determine whether the differences previously seen in antibody outcomes can be determined at the T cell phenotype and antigen-specific level. ..
  22. RISK OF INFECTIOUS DISEASE IN PRISON BASED HCWS
    Robyn Gershon; Fiscal Year: 1999
    ..pathogens (human immunodeficiency virus, hepatitis B and C viruses) and to determine the immune status of hepatitis B vaccines. Additionally, they intend to determine the employees' tuberculin skin test reactivity...
  23. EVALUATE SAFETY OF VACCINES TO PREVENT SHIGELLOSIS
    JUSTEN PASWELL; Fiscal Year: 2000
    ..This project has been approved by the NIH (Protocol Number OH94-CH-NO94) and FDA (BB-IND-4331-S. Sonnei and BB-IND- 3866-S. flexneri). ..
  24. HIV Vaccine Trials in Women
    Beryl Koblin; Fiscal Year: 2006
    ..The primary outcomes to be compared are measures of unprotected sex and vaccine knowledge scores. ..
  25. Nodaviral RNA vaccine vector amplified in yeast
    L Ball; Fiscal Year: 2003
    ..3. To determine immunization routes, schedules, and viral RNA vector formulations that induce significant immune responses to HIV gene products in mice. ..
  26. IMMUNOTHERAPY OF ACUTE LYMPHOCYTIC LEUKEMIA
    Ephraim Fuchs; Fiscal Year: 1999
    ..3) Undertake pilot trials of leukemia cell acquisition, purification, and storage for later use as specific tumor vaccines. ..
  27. Alcohol Use Reduction in Methadone Individuals with HCV
    Adeline Nyamathi; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  28. Community-Based Approach to Designing an AIDS Program for HIV+ Mothers in India
    Adeline Nyamathi; Fiscal Year: 2008
    ..These findings will lead to future funding to actually develop and test a newly designed program. [unreadable] [unreadable] [unreadable]..
  29. TB/HIV RISK REDUCTION WITH HOMELESS AND DRUG ADDICTED
    Adeline Nyamathi; Fiscal Year: 2002
    ....
  30. C-CAPRELA: Cervical Cancer Prevention for Latinas
    SCOTT RHODES; Fiscal Year: 2008
    ..developing effective interventions to reduce those disparities, and facilitating intervention delivery." [unreadable] [unreadable] [unreadable]..
  31. A Culturally Appropriate Cervical Cancer Intervention for Underserved Vietnamese
    Grace X Ma; Fiscal Year: 2010
    ....
  32. Trabajando Juntos: Working for Health Disparity Reduction among Latinos
    SCOTT RHODES; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  33. Hepatitis B ESL Education for Chinese
    Victoria Taylor; Fiscal Year: 2009
    ..Our primary outcome will be HBV serologic testing. Knowledge about key hepatitis B facts will be examined as a secondary outcome. ..
  34. HIV Among Rural Latino Gay Men and MSM in the Southeast
    SCOTT RHODES; Fiscal Year: 2007
    ..Study findings also will help shape new multilevel intervention approaches and strategies to reduce the disproportionate HIV/AIDS disease burden of Latino men. [unreadable] [unreadable] [unreadable]..
  35. Rapid Responses to Problem Drinking on College Campuses
    SCOTT RHODES; Fiscal Year: 2007
    ..Although the environmental intervention should be more than one year, the minimum time would be one academic year with a one year follow up. A pilot study with a historically black college or university is also proposed. ..
  36. IMMUNOGENETIC MECHANISMS OF VACCINE RESPONSE
    Gregory A Poland; Fiscal Year: 2010
    ..The knowledge gained from these studies will enable us to design new strategies and new vaccines to protect human health against viral diseases. ..
  37. Bloodborne Pathogen Risk in Home Healthcare Workers
    Robyn Gershon; Fiscal Year: 2007
    ..This study will improve our understanding of the risks facing home health care workers and allow us to focus our risk management energies and resources appropriately. ..
  38. Cervical Cancer Control in Vietnamese Women
    Victoria Taylor; Fiscal Year: 2007
    ..abstract_text> ..
  39. BLOODBORNE EXPOSURE MANAGEMENT
    Robyn Gershon; Fiscal Year: 2001
    ..This study will identify barriers to appropriate implementation of the Guidelines and allow us to focus our energies and resources on specific improvements in order to minimize the risk of infection to exposed employees. ..
  40. BBP EXPOSURE AND RISK FACTORS IN NON-HOSPITAL BASED HCWS
    Robyn Gershon; Fiscal Year: 2002
    ..This study will improve our understanding of the risks facing non-hospital HCWs and allow us to focus our energies and resources appropriately. ..
  41. Innovative HCW Training: Infectious Disease Risk
    Robyn Gershon; Fiscal Year: 2002
    ..The results of this study may have important implications for effective health and safety training for nurses. ..
  42. ASIAN TOBACCO EDUCATION & CANCER AWARENESS RESEARCH INIT
    Grace Ma; Fiscal Year: 2004
    ..abstract_text> ..
  43. Liver Cancer Control Among North American Chinese
    Victoria Taylor; Fiscal Year: 2006
    ..If effective, our outreach intervention could be used by health care facilities and community organizations serving less acculturated Chinese in North America. ..
  44. Diet and Risk of Ovarian Cancer
    Ellen Chang; Fiscal Year: 2005
    ..The results of the proposed analyses will provide further understanding of the etiology of ovarian cancer. ..
  45. DETERMINING/UNDERSTANDING BARRIERS TO ADULT IMMUNIZATION
    Richard Zimmerman; Fiscal Year: 2001
    ..This project will furnish relevant, up-to-date to enhance policy planning, practice management and medical education. ..
  46. Interventions to Increase HBV Vaccination in STD Clinics
    Gregory Zimet; Fiscal Year: 2006
    ..The relationships of the interventions, socio-demographics, attitudes and behaviors to the outcome measures will be assessed with multiple logistic regression (MLR) and path analysis via structural equation modeling. ..
  47. Aspirin use, genetic variation in aspirin related-genes, and Hodgkin lymphoma ris
    Ellen Chang; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  48. VIRAL HEPATITIS IN CHILDREN OF INJECTION DRUG USERS
    Kathleen Schwarz; Fiscal Year: 2003
    ....
  49. A Randomized Trial of Vaccine Adherence in Young IDU
    Paula Lum; Fiscal Year: 2006
    ..abstract_text> ..
  50. Pegylated Interferon +/- Ribavirin for Children with HCV
    Kathleen Schwarz; Fiscal Year: 2008
    ..Other endpoints include biochemical and clinical safety assessments. This trial would thus provide critically needed data to guide safe and effective treatment of CHC, a major cause of liver disease in children [unreadable] [unreadable]..
  51. HIV Testing and Women's Attitudes on HIV Vaccine Trials
    Gregory D Zimet; Fiscal Year: 2010
    ..abstract_text> ..
  52. The Impact of the FDA Antidepressant Black Box Warning on Psychiatric Practice
    Hua Chen; Fiscal Year: 2007
    ..The study findings will also be a good reference for the policy makers when new black box warning is considered for psychiatric drugs other than antidepressants. [unreadable] [unreadable] [unreadable] [unreadable]..
  53. Molecular basis meningococcal group A capsular immunity
    Dan Granoff; Fiscal Year: 2007
    ..abstract_text> ..
  54. Treatment and Outcome of AIDS-related Lymphoma
    Catherine Diamond; Fiscal Year: 2006
    ..Lastly, we will determine how the use of HAART influences the IPI and develop a prognostic model that incorporates HIV-related factors, tumor characteristics, HAART, and chemotherapy. ..
  55. Electroporation-based delivery of a cancer DNA vaccine
    Alain Luxembourg; Fiscal Year: 2004
    ..End points will include induction of T cell responses, protection against lethal challenge by HPV-induced tumor cells, and eradication of established HPV-induced tumors. ..
  56. Impact of GBV-C infection on perinatal HIV transmission
    Robert Remis; Fiscal Year: 2005
    ..A positive finding would add impetus to additional basic research to elucidate the biologic mechanisms and potentially develop new modatities of prophylaxis and treatment. ..
  57. THE ENDOTHELIAL CELL IN PATHOGENESIS OF TTP
    Jeffrey Laurence; Fiscal Year: 2004
    ..The model presented could also enable exploration of new therapeutic modalities for TTP, based upon modulation of specific apoptotic pathways. ..
  58. Integrating HIV Resistance Data into the CNICS Cohort
    James Kahn; Fiscal Year: 2004
    ..In this application we focus on adding the new data elements of viral resistance to the CNICS research network..
  59. Beta-Catenin Signaling in HBxAg Mediated HCC.
    Mark A Feitelson; Fiscal Year: 2010
    ..In doing so, the proposed work is expected to promote the development of multiple public health benefits for HBV infected carriers with chronic liver disease and HCC. ..